When Will Wegovy Be Available in the UK — and What's Changed

The decision most people are actually weighing

If you've found yourself searching for availability, you're probably frustrated. You may have read about Wegovy online, heard about it from a friend, or spent time on a waiting list already. The honest answer is that the medicine itself has been here for a few years, but getting it through the NHS remains slow for the majority of people, and that gap is where most of the confusion lives.

There are two realistic paths: an NHS referral into a specialist weight management service, or a private prescription through a regulated pharmacy. Neither is right for everyone. Understanding what each requires is the decision worth making first.

If you want to read more about the current state of supply and whether specific doses are accessible right now, our page on whether Wegovy is available now covers that in more detail. For a fuller picture of the medicine itself (how it works, its side effects and what the evidence shows) the Wegovy overview is a good starting point.

What the NHS route looks like in 2025 and 2026

NICE recommended semaglutide (Wegovy) in March 2023 under specific conditions. To qualify on the NHS, you generally need a BMI of 35 or above, at least one weight-related condition, and access to a multidisciplinary specialist weight management service. The recommendation also caps NHS use at two years. Lower BMI thresholds apply for people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, typically 2.5 kg/m² lower across the board. You can read NICE's full criteria in NICE technology appraisal TA875.

Waiting lists for specialist services are often long. From 1 April 2026, GP practices can now prescribe weight management medicines directly under the new GP contract, though participation is optional, and availability varies by area. If your practice has signed up, that can shorten the wait considerably. If it hasn't, you may still face a referral queue. Checking with your GP is the only reliable way to find out which situation applies to you.

For readers in specific parts of the country, our page on Wegovy availability in Wales covers devolved access differences, and you can also check whether there's a provider near you.

The private route and what's changed recently

Private prescriptions through GPhC-registered online pharmacies have made Wegovy accessible to people who meet the licensed eligibility criteria but don't want to wait, or don't meet the NHS thresholds. The licensed criteria for a private prescription broadly follow the SmPC: adults with a BMI of 30 or above, or 27 and above with at least one weight-related condition such as high blood pressure, high cholesterol or type 2 diabetes. A prescriber reviews the full picture, not just the number.

Two significant changes in 2026 have expanded what's available on the private route. The MHRA approved the 7.2 mg single-dose pen in April 2026 (for adults with a BMI of 30 or above) after trial data reported around 20.7% average weight loss over 72 weeks at that dose. Then, in June 2026, the oral Wegovy tablet received UK approval: the first daily pill for weight management based on semaglutide, reaching a 25 mg maintenance dose through a gradual escalation. The tablet requires no refrigeration, which some people find genuinely easier to manage day to day.

For context on what private treatment costs, the cost of Wegovy in the UK page gives an honest breakdown of what pricing typically covers, and what it sometimes doesn't. And if you're curious whether a generic semaglutide might eventually change the landscape, that's a question worth exploring separately.

What a clinical assessment actually involves

Whichever route you consider, the starting point is the same: a prescriber decides whether treatment is appropriate for you. That means looking at your BMI, your medical history, any medicines you already take, and any conditions that might affect suitability. Wegovy is not recommended during pregnancy, while breastfeeding, or if you're trying to conceive. It's also not licensed for under-18s. History of certain conditions (including medullary thyroid carcinoma or pancreatitis) will need to be discussed.

At nume, every consultation is read and assessed the same day by a GPhC-registered Independent Prescriber. There's no algorithm making that call. If approved, treatment is dispatched the same day for orders placed before 12pm on weekdays, arriving free via tracked DPD the next working day. Our clinical team can also answer questions about suitability for semaglutide versus other licensed options, including how semaglutide works in practice. If you're ready to see whether you're eligible, you can check your eligibility through a free consultation.